YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway

Zekun Chen, Qiuju Wu, Ye Ding, Wenhui Zhou, Rong Liu, Haiying Chen, Jia Zhou, Jing Feng, Ceshi Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes. YD277 is a novel small molecule derived from ML264, a KLF5 inhibitor that elicits cytotoxic effects in colon cancer cell lines. Our previous studies suggest that Krüpple-like factor 5 (KLF5) is a promising therapeutic target for TNBC. In this study, we demonstrated that YD277 significantly induced G1 cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 TNBC cells, independent of KLF5 inhibition. YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. Moreover, the pro-apoptotic activity of YD277 in TNBC was mediated by the transcription of IRE1α, a key molecule in the endoplasmic reticulum (ER) stress pathway. Finally, YD277 (15 mg/kg) significantly suppressed the growth of MDA-MB-231 tumor xenografts in nude mice. These findings indicate that YD277 is a promising chemotherapeutic candidate for TNBC.

Original languageEnglish (US)
Pages (from-to)2339-2349
Number of pages11
JournalTheranostics
Volume7
Issue number8
DOIs
StatePublished - Jan 1 2017

Fingerprint

Triple Negative Breast Neoplasms
Endoplasmic Reticulum Stress
G1 Phase Cell Cycle Checkpoints
Cyclin D1
Heterografts
Nude Mice
Colonic Neoplasms
Neoplasms
Apoptosis
Cell Line
Growth
Proteins

Keywords

  • ER stress.
  • IRE1α
  • KLF5
  • Triple-Negative Breast Cancer
  • YD277

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. / Chen, Zekun; Wu, Qiuju; Ding, Ye; Zhou, Wenhui; Liu, Rong; Chen, Haiying; Zhou, Jia; Feng, Jing; Chen, Ceshi.

In: Theranostics, Vol. 7, No. 8, 01.01.2017, p. 2339-2349.

Research output: Contribution to journalArticle

Chen, Zekun ; Wu, Qiuju ; Ding, Ye ; Zhou, Wenhui ; Liu, Rong ; Chen, Haiying ; Zhou, Jia ; Feng, Jing ; Chen, Ceshi. / YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. In: Theranostics. 2017 ; Vol. 7, No. 8. pp. 2339-2349.
@article{7e17a12ab00045e296306993ab443268,
title = "YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway",
abstract = "Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes. YD277 is a novel small molecule derived from ML264, a KLF5 inhibitor that elicits cytotoxic effects in colon cancer cell lines. Our previous studies suggest that Kr{\"u}pple-like factor 5 (KLF5) is a promising therapeutic target for TNBC. In this study, we demonstrated that YD277 significantly induced G1 cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 TNBC cells, independent of KLF5 inhibition. YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. Moreover, the pro-apoptotic activity of YD277 in TNBC was mediated by the transcription of IRE1α, a key molecule in the endoplasmic reticulum (ER) stress pathway. Finally, YD277 (15 mg/kg) significantly suppressed the growth of MDA-MB-231 tumor xenografts in nude mice. These findings indicate that YD277 is a promising chemotherapeutic candidate for TNBC.",
keywords = "ER stress., IRE1α, KLF5, Triple-Negative Breast Cancer, YD277",
author = "Zekun Chen and Qiuju Wu and Ye Ding and Wenhui Zhou and Rong Liu and Haiying Chen and Jia Zhou and Jing Feng and Ceshi Chen",
year = "2017",
month = "1",
day = "1",
doi = "10.7150/thno.17555",
language = "English (US)",
volume = "7",
pages = "2339--2349",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "8",

}

TY - JOUR

T1 - YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway

AU - Chen, Zekun

AU - Wu, Qiuju

AU - Ding, Ye

AU - Zhou, Wenhui

AU - Liu, Rong

AU - Chen, Haiying

AU - Zhou, Jia

AU - Feng, Jing

AU - Chen, Ceshi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes. YD277 is a novel small molecule derived from ML264, a KLF5 inhibitor that elicits cytotoxic effects in colon cancer cell lines. Our previous studies suggest that Krüpple-like factor 5 (KLF5) is a promising therapeutic target for TNBC. In this study, we demonstrated that YD277 significantly induced G1 cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 TNBC cells, independent of KLF5 inhibition. YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. Moreover, the pro-apoptotic activity of YD277 in TNBC was mediated by the transcription of IRE1α, a key molecule in the endoplasmic reticulum (ER) stress pathway. Finally, YD277 (15 mg/kg) significantly suppressed the growth of MDA-MB-231 tumor xenografts in nude mice. These findings indicate that YD277 is a promising chemotherapeutic candidate for TNBC.

AB - Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes. YD277 is a novel small molecule derived from ML264, a KLF5 inhibitor that elicits cytotoxic effects in colon cancer cell lines. Our previous studies suggest that Krüpple-like factor 5 (KLF5) is a promising therapeutic target for TNBC. In this study, we demonstrated that YD277 significantly induced G1 cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 TNBC cells, independent of KLF5 inhibition. YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. Moreover, the pro-apoptotic activity of YD277 in TNBC was mediated by the transcription of IRE1α, a key molecule in the endoplasmic reticulum (ER) stress pathway. Finally, YD277 (15 mg/kg) significantly suppressed the growth of MDA-MB-231 tumor xenografts in nude mice. These findings indicate that YD277 is a promising chemotherapeutic candidate for TNBC.

KW - ER stress.

KW - IRE1α

KW - KLF5

KW - Triple-Negative Breast Cancer

KW - YD277

UR - http://www.scopus.com/inward/record.url?scp=85035117746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035117746&partnerID=8YFLogxK

U2 - 10.7150/thno.17555

DO - 10.7150/thno.17555

M3 - Article

VL - 7

SP - 2339

EP - 2349

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 8

ER -